| Latest Genvec News Headlines | | Date | Time | Source | | | 10/22/2009 | 8:17AM | PRNUS | GenVec to Present at the BIO Investor Forum
GAITHERSBURG, Md., Oct. 22 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (NASDAQ:GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the BIO Investor Forum on Thursday, October 29, 2009 at 12:00 pm PST at The Palace Hotel in San Francisco... More...>> |
| 09/30/2009 | 7:43AM | PRNUS | GenVec Receives National Cancer Institute Grant to Expand Cancer Program
GAITHERSBURG, Md., Sept. 30 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ:GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating... More...>> |
| 09/24/2009 | 7:30AM | PRNUS | GenVec Receives Fourth-Year Funding From NIAID For HIV Vaccine Contract
GAITHERSBURG, Md., Sept. 24 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ:GNVC) announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its third option period (year four) under a previously announced, five-year contract with... More...>> |
| 07/27/2009 | 7:55AM | PRNUS | GenVec Expands Contract Supporting Malaria Vaccine Program
GAITHERSBURG, Md., July 27 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (NASDAQ:GNVC) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million... More...>> |
| 08/01/2008 | 9:57AM | PRNUS | BeaconEquity.com Issues Technical Trade Alerts on Market Movers: ZONS, SSCC, VNDA, DSTI, XOMA, GNVC
DALLAS, Aug. 1 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://beaconequity.com/m
Today's Trade Alerts include: Zones Inc. (NASDAQ:ZONS), Smurfit-Stone Container Corp. (NASDAQ:SSCC... More...>> |
| 06/09/2005 | 9:45AM | PRNUS | TransMolecular Appoints E. Michael Egan as Chief Executive Officer
TransMolecular Appoints E. Michael Egan as Chief Executive
Officer
Seasoned Drug Commercialization Executive Brings 25 Years of Academic and
Industrial Biotechnology Experience
BIRMINGHAM, Ala., June 9 /PRNewswire/ -- TransMolecular, Inc., a biotechnology
company focused on cancer drug research, today announced the... More...>> |
| 04/15/2005 | 8:00AM | PRNUS | Results From Phase I HIV Vaccine Study Reported at Keystone Symposium
Results From Phase I HIV Vaccine Study Reported at Keystone
Symposium
GAITHERSBURG, Md., April 15 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) announced that safety and immune response data were presented
from the first of several ongoing Phase I clinical trials involving an HIV
vaccine candidate developed jointly... More...>> |
| 03/10/2005 | 3:49PM | PRNUS | GenVec to Present at SQ Cowen & Co. 25th Annual Healthcare Conference
GenVec to Present at SQ Cowen & Co. 25th Annual Healthcare
Conference
GAITHERSBURG, Md., March 10 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) today announced that the Company's President and CEO, Paul H.
Fischer, Ph.D., will present a corporate update at the SG Cowen & Co. 25th
Annual Healthcare Conference... More...>> |
| 03/09/2005 | 4:05PM | PRNUS | GenVec Reports Fourth Quarter and 2004 Year End Financial Results
GenVec Reports Fourth Quarter and 2004 Year End Financial Results
GAITHERSBURG, Md., March 9 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC), today announced financial results for the fourth quarter and
year ended December 31, 2004. For the year ended December 31, 2004, the
company reported a net loss of $18.9... More...>> |
| 03/08/2005 | 2:15PM | PRNUS | Three Year Phase I Myoblast Cell Transplantation Study Data Presented at American College of Cardiology Scientific Sessions
Three Year Phase I Myoblast Cell Transplantation Study Data
Presented at American College of Cardiology Scientific Sessions
Findings Highlighted at ACC Press Briefing
GAITHERSBURG, Md., March 8 /PRNewswire/ -- GenVec, Inc. (NASDAQ:GNVC),
announced that three year follow-up data from a Phase I study of its myoblast
cell... More...>> |
| 03/02/2005 | 8:00AM | PRNUS | GenVec Launches Phase IIB Trial in Patients With Severe Coronary Artery Disease
GenVec Launches Phase IIB Trial in Patients With Severe Coronary
Artery Disease
GAITHERSBURG, Md., March 2 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) today announced the launch of a Phase IIB randomized, placebo-
controlled trial of its BIOBYPASS(R) angiogen for the treatment of severe
coronary artery disease.
The... More...>> |
| 03/01/2005 | 3:32PM | PRNUS | GenVec Invites You to Join Its Fourth Quarter and Year-End 2004 Earnings Call and Webcast
GenVec Invites You to Join Its Fourth Quarter and Year-End 2004
Earnings Call and Webcast
GAITHERSBURG, Md., March 1 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) announced that it will release its financial results for the
fourth quarter and year ended December 31, 2004 on Wednesday, March 9, 2005
after the... More...>> |
| 02/22/2005 | 8:01AM | PRNUS | GenVec Expands Clinical Testing of AdPEDF for Macular Degeneration
GenVec Expands Clinical Testing of AdPEDF for Macular
Degeneration
GAITHERSBURG, Md., Feb. 22 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) today announced that it has begun the second part of the ongoing
Phase I clinical trial of its pigment epithelium-derived factor (AdPEDF) drug
candidate for wet age-related... More...>> |
| 02/18/2005 | 1:34PM | PRNUS | GenVec to Participate in Focus Session at the BIO CEO & Investor Conference
GenVec to Participate in Focus Session at the BIO CEO & Investor
Conference
GAITHERSBURG, Md., Feb. 18 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) today announced that the Company's President and CEO, Paul H.
Fischer, Ph.D., will participate as a panelist in a focus session at the BIO
CEO & Investor Conference... More...>> |
| 02/14/2005 | 1:30PM | PRNUS | GenVec Announces Publication of Hearing Loss Research
GenVec Announces Publication of Hearing Loss Research
Preclinical Findings Suggest Novel Approach to Treatment
GAITHERSBURG, Md., Feb. 14 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) today reported that encouraging preclinical findings on a novel
approach to treating hearing loss have been published in the March... More...>> |
| 02/11/2005 | 1:31PM | PRNUS | GenVec Receives FDA Clearance to Proceed With the Randomized Portion of the Phase II Clinical Study of TNFerade(TM) in Pancreati
GenVec Receives FDA Clearance to Proceed With the Randomized
Portion of the Phase II Clinical Study of TNFerade(TM) in Pancreatic Cancer
GAITHERSBURG, Md., Feb. 11 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) announced that it has received a letter from the U.S. Food and
Drug Administration (FDA) today, which... More...>> |
| 01/20/2005 | 8:00AM | PRNUS | GenVec Expands Malaria Vaccine Program Under U.S. Naval Medical Research Center Contract
GenVec Expands Malaria Vaccine Program Under U.S. Naval Medical
Research Center Contract
GAITHERSBURG, Md., Jan. 20 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) has signed a $1.6 million contract with the Department of Defense
to manufacture an adenovector based malaria vaccine candidate for the U.S.
Naval Medical... More...>> |
| 01/19/2005 | 8:00AM | PRNUS | NIH Begins Second Phase I Clinical Trial of HIV Vaccine Produced in Collaboration With GenVec
NIH Begins Second Phase I Clinical Trial of HIV Vaccine Produced
in Collaboration With GenVec
GAITHERSBURG, Md., Jan. 19 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) announced today that the National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH), has begun the
second... More...>> |
| 01/12/2005 | 8:00AM | PRNUS | Next Generation HIV Vaccine Research Collaboration Between Vaccine Research Center and GenVec Under New Contract Extension
Next Generation HIV Vaccine Research Collaboration Between
Vaccine Research Center and GenVec Under New Contract Extension
GAITHERSBURG, Md., Jan. 12 /PRNewswire-FirstCall/ -- GenVec, Inc.
(NASDAQ:GNVC) announced a $10 million one-year contract extension of its HIV
vaccine development work with the Vaccine Research... More...>> |
| 12/07/2004 | 8:01AM | PRNUS | GenVec Receives National Eye Institute Grant for Its Ocular Program
GenVec Receives National Eye Institute Grant for Its Ocular
Program
GAITHERSBURG, Md., Dec. 7 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ:GNVC)
announced that it has received a two-year, $750,000 Small Business and
Innovative Research (SBIR) grant from the National Eye Institute (NEI) to
support research on the biological... More...>> |
|